<DOC>
	<DOCNO>NCT00466583</DOCNO>
	<brief_summary>This Phase 1 , open-label , non-randomized , dose-escalation study determine maximum tolerate dose ( MTD ) , safety , tolerance , pharmacologic profile EZN-2968 , lock nucleic acid antisense oligonucleotide hypoxia-inducible factor 1α administer 2-hour intravenous ( i.v . ) infusion weekly 3 week per 6-week cycle . In patient treat recommend Phase 2 dose EZN-2968 , dose intensification proceed maintain dose , gradually increase number dos per 6-week cycle . Up 3 intensification cohort receive recommend Phase 2 dose EZN-2968 .</brief_summary>
	<brief_title>Phase 1 Study EZN-2968 Weekly Adult Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>This Phase 1 , open-label , non-randomized , dose-escalation study determine maximum tolerate dose ( MTD ) , safety , tolerance , pharmacologic profile EZN-2968 , lock nucleic acid antisense oligonucleotide hypoxia-inducible factor 1α ( anti-HIF-1α LNA AS ODN ) administer 2-hour intravenous ( i.v . ) infusion weekly 3 week per 6-week cycle . In patient treat recommend Phase 2 dose EZN-2968 , dose intensification proceed maintain dose , gradually increase number dos per 6-week cycle . Up 3 intensification cohort receive recommend Phase 2 dose EZN-2968 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients must meet follow criterion eligible enrollment study . Histologically cytologically confirm diagnosis advance and/or metastatic solid tumor lymphoma ( Hodgkin 's nonHodgkin 's ) Patients failed standard therapy know effective therapy available Patients may tumor amenable biopsy Measurable evaluable disease . Age 18 year old Patients meet follow exclusion criterion eligible enrollment . Concurrent serious medical illness Known , clinically suspect , history central nervous system ( CNS ) tumor involvement Prior chemotherapy , immunotherapy , investigational agent , therapy use treat cancer within 4 week ( 6 week prior treatment mitomycin C nitrosoureas ) schedule administration EZN2968 . Luteinizing hormonereleasing hormone ( LHRH ) agonist therapy permit patient hormone refractory prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Carcinoma , Lymphoma</keyword>
</DOC>